- Conditions
- Psoriasis
- Interventions
- Topical Therapy, Phototherapy and Systemic Therapy, Biologic Therapy
- Other
- Lead sponsor
- University of California, Irvine
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Irvine, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 101
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Plaque Psoriasis
- Interventions
- 210 mg brodalumab, 140 mg brodalumab, ustekinumab, placebo
- Drug
- Lead sponsor
- Bausch Health Americas, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,881 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 66 more
- Conditions
- Healthy
- Interventions
- Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014
- U.S. locations
- 3
- States / cities
- Tempe, Arizona • Lincoln, Nebraska • Neptune City, New Jersey
- Conditions
- Crohn Disease
- Interventions
- Ustekinumab 90 mg, Ustekinumab 4.5 mg/kg, Placebo SC, Placebo IV
- Drug
- Lead sponsor
- Centocor, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 50
- States / cities
- Scottsdale, Arizona • Anaheim, California • Sacramento, California + 47 more
- Conditions
- Crohn Disease
- Interventions
- Ustekinumab
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • New York, New York
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Placebo + methotrexate (MTX) (Group 1), Ustekinumab + MTX (Group 2), Ustekinumab + MTX (Group 3), CNTO 1959 + MTX (Group 4), CNTO 1959 + MTX (Group 5)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 3
- States / cities
- Palm Harbor, Florida • Rock Island, Illinois • St Louis, Missouri
- Conditions
- Moderate to Severe Chronic Plaque Psoriasis
- Interventions
- Stelara, Bmab1200
- Biological
- Lead sponsor
- Biocon Biologics UK Ltd
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 384 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Mayfield Heights, Ohio
- Conditions
- Lupus Erythematosus, Systemic
- Interventions
- Ustekinumab IV, Placebo Infusion, Placebo SC, Ustekinumab SC, Concomitant Medication
- Drug · Other
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 12
- States / cities
- Huntsville, Alabama • Beverly Hills, California • Tampa, Florida + 9 more
- Conditions
- Crohn Disease
- Interventions
- Low serine diet, High serine diet
- Dietary Supplement
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Colitis, Ulcerative
- Interventions
- Treatment Algorithm A, Treatment Algorithm B, Treatment Algorithm C
- Biological
- Lead sponsor
- Alimentiv Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 672 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 5
- States / cities
- Ypsilanti, Michigan • New York, New York • Asheville, North Carolina + 1 more
- Conditions
- Crohn's Disease, Ulcerative Colitis
- Interventions
- Not listed
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- New York, New York • Chapel Hill, North Carolina
- Conditions
- Active Psoriatic Arthritis
- Interventions
- BMS-986165 Placebo, BMS-986165 Dose A, BMS-986165 Dose B, Ustekinumab, Ustekinumab Placebo
- Other · Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 203 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 31
- States / cities
- Huntsville, Alabama • Covina, California • La Jolla, California + 27 more
- Conditions
- Cancer
- Interventions
- Ustekinumab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Psoriasis
- Interventions
- Ustekinumab
- Drug
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Crohn Disease, Ulcerative Colitis
- Interventions
- Ustekinumab IV Infusion, Ustekinumab SC Injection, Midazolam 2 mg, Warfarin 10 mg, Vitamin K 10 mg, Omeprazole 20 mg, Dextromethorphan 30 mg, Caffeine 100 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 28 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 3
- States / cities
- Cypress, California • Miami Springs, Florida • Durham, North Carolina
- Conditions
- Arthritis, Juvenile
- Interventions
- Ustekinumab, Guselkumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2026
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Boston, Massachusetts • New York, New York + 5 more
- Conditions
- Psoriasis
- Interventions
- Not listed
- Lead sponsor
- Janssen Scientific Affairs, LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 20,167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2030
- U.S. locations
- 167
- States / cities
- Birmingham, Alabama • Florence, Alabama • Huntsville, Alabama + 164 more
- Conditions
- Rheumatic Disease
- Interventions
- Methotrexate, Sulfasalazine, Hydroxychloroquine, Leflunomide, Azathioprine, Mycophenolate, Cyclosporine, Tacrolimus, Etanercept, Adalimumab, Golimumab, Certolizumab, Infliximab, Rituximab, Belimumab, Tocilizumab, Anakinra, Canakinumab, Abatacept, Secukinumab, Ixekizumab, Bimekizumab, Ustekinumab, Guselkumab, Risankizumab, Tofacitinib, Upadacitinib
- Drug · Biological
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Crohn Disease
- Interventions
- BI 706321, Ustekinumab, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 15
- States / cities
- Northridge, California • Hialeah, Florida • Inverness, Florida + 12 more
- Conditions
- Crohn Disease
- Interventions
- JNJ-64304500, Placebo, Adalimumab, Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Plaque Psoriasis
- Interventions
- Secukinumab, Ustekinumab
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,114 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 123
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 103 more
- Conditions
- Crohn Disease
- Interventions
- JNJ-64304500, Placebo, Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 388 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 37
- States / cities
- Lone Tree, Colorado • Coral Gables, Florida • Kissimmee, Florida + 34 more
- Conditions
- Juvenile Psoriatic Arthritis, Psoriasis, Arthritis, Juvenile
- Interventions
- Ustekinumab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 5 Years to 17 Years
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 10
- States / cities
- Huntington Beach, California • Los Angeles, California • Chicago, Illinois + 6 more
- Conditions
- Crohn Disease
- Interventions
- Ustekinumab approximately 6 mg/kg (IV), Placebo (SC), Placebo (IV), Ustekinumab 90 mg (SC) Group 1, Ustekinumab 90 mg (SC) Group 2
- Drug
- Lead sponsor
- Janssen-Cilag Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 28
- States / cities
- La Jolla, California • Colorado Springs, Colorado • Gainesville, Florida + 22 more